Company Insights

REVB supplier relationships

Explore interactive graphBrowse insights index
REVB supplier relationship map

Revelation Biosciences (REVB) — supplier and services map for investors

Revelation Biosciences is a clinical‑stage biopharmaceutical developer focused on immunological diagnostics and therapeutics, funding operations through capital markets transactions and milestone‑driven financing while outsourcing virtually all manufacturing, investor relations, transfer agent, audit and advisory functions. The company monetizes long‑term value by advancing its GEM program and other candidates toward regulatory approval, while near‑term liquidity is managed through exercises of warrants and advisor‑led capital raises. Visit https://nullexposure.com/ for deeper supplier intelligence and alerts.

Why suppliers matter for a clinical‑stage biotech like REVB

Revelation operates with a conventional biotech contracting posture: no internal commercial manufacturing, heavy third‑party reliance, and short‑term/cancellable commercial arrangements. That posture reduces fixed cost but concentrates operational risk—particularly where single‑source components or vendors exist. The firm reports no product revenue to date and negative EBITDA and EPS, so supplier continuity and cost of capital directly impact its runway and program timelines.

  • Contracting posture: Contracts are frequently short‑term or cancellable, meaning the company retains flexibility but has limited supply lock‑in.
  • Concentration risk: The company explicitly names a sole supplier for PHAD® (Avanti Polar Lipids), signaling a realistic single‑source vulnerability.
  • Critical outsourcing: Manufacturing for clinical materials and any future commercial supply is outsourced and described as critical to program progression.
  • Maturity and stage: Active manufacturing relationships support ongoing GEM program clinical batches, consistent with a company transitioning from discovery to later‑stage clinical operations.

These operating characteristics translate into a supplier risk profile where procurement agility, contingency sourcing and financing cost are equally important as scientific progress. If you want a structured watchlist and alerts for these relationships, see https://nullexposure.com/.

Supplier and service‑provider map: who does business with REVB

Baker Tilly US, LLP

Baker Tilly served as Revelation’s independent registered public accounting firm for the years ended December 31, 2024 and 2023, reflecting a conventional auditor relationship required for public reporting. This is disclosed in the company’s FY2024 Form 10‑K filing. (FY2024 10‑K)

Roth Capital Partners

Roth Capital Partners acted as the company’s financial advisor on a March 2026 transaction tied to warrant exercises that generated approximately $11 million in gross proceeds; press reports also note Revelation agreed to pay an 8% cash fee on gross proceeds under the engagement. (Press releases and news reports, March 2026 — Progress‑Index / HeraldTribune / TradingView)

Continental Stock Transfer & Trust Co.

Continental Stock Transfer & Trust Co. is named as the company’s transfer agent and will maintain book‑entry records for common stock following a 1‑for‑4 reverse split announced in March 2026, a standard custodial role for equity recordkeeping. (Newswire release on the reverse stock split, March 2026)

Porter LaVay & Rose Inc.

Porter LaVay & Rose (listed repeatedly in multiple March 2026 press releases) functions as Revelation’s investor relations and PR contact with Mike Porter identified as the primary company contact for investor communications and conference presentations. The firm appears on earnings announcements, event presentations and corporate news. (Multiple press releases and conference notices, March 2026)

Porter LeVay & Rose Inc.

A variant spelling of the investor relations firm — Porter LeVay & Rose — is also listed on a company financial results release, indicating the same investor relations function across multiple disclosures and newswire distributions. (Newswire financial results release, March 2026)

XPR Media

XPR Media distributed a January 7, 2026 press release for Revelation announcing initiation of GMP manufacturing of Gemini and placebo to support later‑stage clinical development, serving as a press distribution partner for corporate milestones. (Press release distributed January 7, 2026)

ACCESS Newswire

An ACCESS Newswire distribution on January 7, 2026 carried a corporate announcement that included the company’s NASDAQ ticker (REVB), confirming use of wire services for SEC‑relevant and investor communications. (ACCESS Newswire distribution, January 7, 2026)

How the relationship map influences investment risk and operational execution

Revelation’s supplier map is dominated by service providers that support regulatory reporting, capital formation and market communications rather than vertical integration. That structure accelerates scalability when programs advance but creates explicit dependency vectors:

  • Manufacturing dependency is critical and concentrated. The company outsources clinical and potentially commercial manufacturing and identifies only one supplier for a key raw material (PHAD®), which creates a single‑point failure for clinical timelines unless alternative sources are qualified rapidly.
  • Short‑term, cancellable contracts lower fixed commitments but increase re‑procurement execution risk. The 10‑K discloses use of purchase orders and lease exceptions under 12 months; this lowers balance sheet commitments but requires robust supplier management to avoid supply interruptions.
  • Financial advisor and PR engagement signals active capital management. Roth Capital’s advisory role on a material warrant exercise and the repeated use of Porter LaVay & Rose for investor outreach show the company is balancing program spend with market communications to manage liquidity.
  • Operational maturity is transitional. Active third‑party manufacturing for GEM‑AKI, GEM‑CKD and GEM‑PSI indicates the company is past discovery and running clinical manufacturing campaigns, but no long‑term manufacturing agreements are in place, placing premium on contingency planning and the cost of capital.

Investment takeaways and actionable signals

  • Key exposure: single‑source materials and outsourced manufacturing. Investors should monitor supplier substitution plans and any long‑term manufacturing agreements; absence of these increases program execution risk.
  • Balance sheet sensitivity to financing costs. The use of warrant exercises and an 8% cash fee to Roth Capital for financing suggests capital raises are material to near‑term runway and that financing friction will affect burn management.
  • Standard public‑company service providers are in place. Auditor, transfer agent and IR engagements are conventional and do not present unusual counterparty risk but are important for governance and market access.

If you track counterparty concentration or want alerts when a supplier relationship changes, check https://nullexposure.com/ for monitoring and supplier risk scoring.

Revelation’s commercial model is typical for a small clinical‑stage biotech: outsized operational dependence on a handful of third parties, active capital markets engagement to fund development, and program value contingent on uninterrupted supply and successful trial progression. For investors, diligence should focus equally on development milestones and supplier continuity plans.